Cargando…

Metabolomics approach reveals effects of antihypertensives and lipid-lowering drugs on the human metabolism

The mechanism of antihypertensive and lipid-lowering drugs on the human organism is still not fully understood. New insights on the drugs’ action can be provided by a metabolomics-driven approach, which offers a detailed view of the physiological state of an organism. Here, we report a metabolome-wi...

Descripción completa

Detalles Bibliográficos
Autores principales: Altmaier, Elisabeth, Fobo, Gisela, Heier, Margit, Thorand, Barbara, Meisinger, Christine, Römisch-Margl, Werner, Waldenberger, Melanie, Gieger, Christian, Illig, Thomas, Adamski, Jerzy, Suhre, Karsten, Kastenmüller, Gabi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Netherlands 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4050296/
https://www.ncbi.nlm.nih.gov/pubmed/24816436
http://dx.doi.org/10.1007/s10654-014-9910-7
_version_ 1782319931858092032
author Altmaier, Elisabeth
Fobo, Gisela
Heier, Margit
Thorand, Barbara
Meisinger, Christine
Römisch-Margl, Werner
Waldenberger, Melanie
Gieger, Christian
Illig, Thomas
Adamski, Jerzy
Suhre, Karsten
Kastenmüller, Gabi
author_facet Altmaier, Elisabeth
Fobo, Gisela
Heier, Margit
Thorand, Barbara
Meisinger, Christine
Römisch-Margl, Werner
Waldenberger, Melanie
Gieger, Christian
Illig, Thomas
Adamski, Jerzy
Suhre, Karsten
Kastenmüller, Gabi
author_sort Altmaier, Elisabeth
collection PubMed
description The mechanism of antihypertensive and lipid-lowering drugs on the human organism is still not fully understood. New insights on the drugs’ action can be provided by a metabolomics-driven approach, which offers a detailed view of the physiological state of an organism. Here, we report a metabolome-wide association study with 295 metabolites in human serum from 1,762 participants of the KORA F4 (Cooperative Health Research in the Region of Augsburg) study population. Our intent was to find variations of metabolite concentrations related to the intake of various drug classes and—based on the associations found—to generate new hypotheses about on-target as well as off-target effects of these drugs. In total, we found 41 significant associations for the drug classes investigated: For beta-blockers (11 associations), angiotensin-converting enzyme (ACE) inhibitors (four assoc.), diuretics (seven assoc.), statins (ten assoc.), and fibrates (nine assoc.) the top hits were pyroglutamine, phenylalanylphenylalanine, pseudouridine, 1-arachidonoylglycerophosphocholine, and 2-hydroxyisobutyrate, respectively. For beta-blockers we observed significant associations with metabolite concentrations that are indicative of drug side-effects, such as increased serotonin and decreased free fatty acid levels. Intake of ACE inhibitors and statins associated with metabolites that provide insight into the action of the drug itself on its target, such as an association of ACE inhibitors with des-Arg(9)-bradykinin and aspartylphenylalanine, a substrate and a product of the drug-inhibited ACE. The intake of statins which reduce blood cholesterol levels, resulted in changes in the concentration of metabolites of the biosynthesis as well as of the degradation of cholesterol. Fibrates showed the strongest association with 2-hydroxyisobutyrate which might be a breakdown product of fenofibrate and, thus, a possible marker for the degradation of this drug in the human organism. The analysis of diuretics showed a heterogeneous picture that is difficult to interpret. Taken together, our results provide a basis for a deeper functional understanding of the action and side-effects of antihypertensive and lipid-lowering drugs in the general population. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s10654-014-9910-7) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4050296
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Springer Netherlands
record_format MEDLINE/PubMed
spelling pubmed-40502962014-06-18 Metabolomics approach reveals effects of antihypertensives and lipid-lowering drugs on the human metabolism Altmaier, Elisabeth Fobo, Gisela Heier, Margit Thorand, Barbara Meisinger, Christine Römisch-Margl, Werner Waldenberger, Melanie Gieger, Christian Illig, Thomas Adamski, Jerzy Suhre, Karsten Kastenmüller, Gabi Eur J Epidemiol Genetic Epidemiology The mechanism of antihypertensive and lipid-lowering drugs on the human organism is still not fully understood. New insights on the drugs’ action can be provided by a metabolomics-driven approach, which offers a detailed view of the physiological state of an organism. Here, we report a metabolome-wide association study with 295 metabolites in human serum from 1,762 participants of the KORA F4 (Cooperative Health Research in the Region of Augsburg) study population. Our intent was to find variations of metabolite concentrations related to the intake of various drug classes and—based on the associations found—to generate new hypotheses about on-target as well as off-target effects of these drugs. In total, we found 41 significant associations for the drug classes investigated: For beta-blockers (11 associations), angiotensin-converting enzyme (ACE) inhibitors (four assoc.), diuretics (seven assoc.), statins (ten assoc.), and fibrates (nine assoc.) the top hits were pyroglutamine, phenylalanylphenylalanine, pseudouridine, 1-arachidonoylglycerophosphocholine, and 2-hydroxyisobutyrate, respectively. For beta-blockers we observed significant associations with metabolite concentrations that are indicative of drug side-effects, such as increased serotonin and decreased free fatty acid levels. Intake of ACE inhibitors and statins associated with metabolites that provide insight into the action of the drug itself on its target, such as an association of ACE inhibitors with des-Arg(9)-bradykinin and aspartylphenylalanine, a substrate and a product of the drug-inhibited ACE. The intake of statins which reduce blood cholesterol levels, resulted in changes in the concentration of metabolites of the biosynthesis as well as of the degradation of cholesterol. Fibrates showed the strongest association with 2-hydroxyisobutyrate which might be a breakdown product of fenofibrate and, thus, a possible marker for the degradation of this drug in the human organism. The analysis of diuretics showed a heterogeneous picture that is difficult to interpret. Taken together, our results provide a basis for a deeper functional understanding of the action and side-effects of antihypertensive and lipid-lowering drugs in the general population. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s10654-014-9910-7) contains supplementary material, which is available to authorized users. Springer Netherlands 2014-05-10 2014 /pmc/articles/PMC4050296/ /pubmed/24816436 http://dx.doi.org/10.1007/s10654-014-9910-7 Text en © The Author(s) 2014 https://creativecommons.org/licenses/by/4.0/ Open AccessThis article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.
spellingShingle Genetic Epidemiology
Altmaier, Elisabeth
Fobo, Gisela
Heier, Margit
Thorand, Barbara
Meisinger, Christine
Römisch-Margl, Werner
Waldenberger, Melanie
Gieger, Christian
Illig, Thomas
Adamski, Jerzy
Suhre, Karsten
Kastenmüller, Gabi
Metabolomics approach reveals effects of antihypertensives and lipid-lowering drugs on the human metabolism
title Metabolomics approach reveals effects of antihypertensives and lipid-lowering drugs on the human metabolism
title_full Metabolomics approach reveals effects of antihypertensives and lipid-lowering drugs on the human metabolism
title_fullStr Metabolomics approach reveals effects of antihypertensives and lipid-lowering drugs on the human metabolism
title_full_unstemmed Metabolomics approach reveals effects of antihypertensives and lipid-lowering drugs on the human metabolism
title_short Metabolomics approach reveals effects of antihypertensives and lipid-lowering drugs on the human metabolism
title_sort metabolomics approach reveals effects of antihypertensives and lipid-lowering drugs on the human metabolism
topic Genetic Epidemiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4050296/
https://www.ncbi.nlm.nih.gov/pubmed/24816436
http://dx.doi.org/10.1007/s10654-014-9910-7
work_keys_str_mv AT altmaierelisabeth metabolomicsapproachrevealseffectsofantihypertensivesandlipidloweringdrugsonthehumanmetabolism
AT fobogisela metabolomicsapproachrevealseffectsofantihypertensivesandlipidloweringdrugsonthehumanmetabolism
AT heiermargit metabolomicsapproachrevealseffectsofantihypertensivesandlipidloweringdrugsonthehumanmetabolism
AT thorandbarbara metabolomicsapproachrevealseffectsofantihypertensivesandlipidloweringdrugsonthehumanmetabolism
AT meisingerchristine metabolomicsapproachrevealseffectsofantihypertensivesandlipidloweringdrugsonthehumanmetabolism
AT romischmarglwerner metabolomicsapproachrevealseffectsofantihypertensivesandlipidloweringdrugsonthehumanmetabolism
AT waldenbergermelanie metabolomicsapproachrevealseffectsofantihypertensivesandlipidloweringdrugsonthehumanmetabolism
AT giegerchristian metabolomicsapproachrevealseffectsofantihypertensivesandlipidloweringdrugsonthehumanmetabolism
AT illigthomas metabolomicsapproachrevealseffectsofantihypertensivesandlipidloweringdrugsonthehumanmetabolism
AT adamskijerzy metabolomicsapproachrevealseffectsofantihypertensivesandlipidloweringdrugsonthehumanmetabolism
AT suhrekarsten metabolomicsapproachrevealseffectsofantihypertensivesandlipidloweringdrugsonthehumanmetabolism
AT kastenmullergabi metabolomicsapproachrevealseffectsofantihypertensivesandlipidloweringdrugsonthehumanmetabolism